StartseiteMCPWorkbenchSkills
StartseiteWorkbenchBenachrichtigungenMein Bereich
Huagongshe Open Project：[email protected]KI-Anbindung: llms.txt · MCP-AnleitungDatenschutz · Nutzungsbedingungen · Supportv1.7.9
  1. Startseite
  2. /Verbindung

Ozenoxacin

HCID 9863827
Neue NotizNeue ReaktionAnfrage stellenDruckvorschau
GrundinformationenÜberblickNamen und BezeichnerEigenschaftenSicherheit und RegulatorischesChemie und IndustrieZugehörige ReaktionenNotizen zur Verbindung
TeilstruktursucheÄhnliche Strukturen suchen

Grundinformationen

CAS
245765-41-7
Standard-SMILES
CNc1ncc(-c2ccc3c(=O)c(C(=O)O)cn(C4CC4)c3c2C)cc1C
InChIKey
XPIJWUTXQAGSLK-UHFFFAOYSA-N
Summenformel
C21H21N3O3
Durchschnittliche Molmasse
363,4 g/mol
Monoisotopische Masse
363,15829154

Überblick

Ozenoxacin is a member of quinolines.

Namen und Bezeichner

Bevorzugter Name
Ozenoxacin
IUPAC
1-cyclopropyl-8-methyl-7-[5-methyl-6-(methylamino)-3-pyridinyl]-4-oxoquinoline-3-carboxylic acid
Englischer Name
Ozenoxacin
Summenformel
C21H21N3O3
Molmasse
363.41

Namen und Synonyme

Ozenoxacin245765-41-7Xepi1-cyclopropyl-8-methyl-7-(5-methyl-6-(methylamino)pyridin-3-yl)-4-oxo-1,4-dihydroquinoline-3-carboxylic acidT-3912ozenoxacineOzenoxacino1-cyclopropyl-8-methyl-7-[5-methyl-6-(methylamino)pyridin-3-yl]-4-oxoquinoline-3-carboxylic acidV0LH498RFOGF-001001-00DTXSID009474461-cyclopropyl-8-methyl-7-[5-methyl-6-(methylamino)pyridin-3-yl]-4-oxo-1,4-dihydroquinoline-3-carboxylic acid
Weitere Namen anzeigen
OzefloxacinT 3912M-5120OzoxacinOxazacinGF-00100100OzofloxacinOzenoxacin, >
1-cyclopropyl-8-methyl-7-(5-methyl-6-(methylamino)-3-pyridinyl)-4-oxo-1,4-dihydro-3-quinolinecarboxylic acidozenoxacinum1-cyclopropyl-8-methyl-7-(5-methyl-6-(methylamino)pyridin-3-yl)-4-oxoquinoline-3-carboxylic acidRefChem:57815D06AX14DTXCID101375704MFCD18633255Ozenoxacin Cream

Datenbank-Bezeichner

CAS

Eigenschaften

Berechnete Struktureigenschaften

XLogP
4,1
Polarare Oberfläche (TPSA)
82,5 Ų
H-Brücken-Donoren
2
H-Brücken-Akzeptoren
6
Frei drehbare Bindungen
4
Schwere Atome
27
Formalladung
0
Komplexität
645

Experimentelle und physikochemische Eigenschaften

DrugsPharmaceuticals -> Listed in ZINC15
Human Drugs · 3 Einträge

Breast Feeding; Lactation; Quinolones; Anti-Infective Agents, Local; Anti-Bacterial Agents;

FDA approved drugs -> Active ingredient

FDA approved drugs -> Active ingredient

Physikochemische Eigenschaften

Schmelzpunkt
255 °C · >255°C (dec.)
Siedepunkt
573.5 · 573.5±50.0 °C(Predicted)
Dichte
1.372 · 1.372±0.06 g/cm3(Predicted)
storage temp.
2 · 2-8°C(protect from light)
Löslichkeit
DMSO (Slightly)
pka
6.46 · 6.46±0.50(Predicted)
Aggregatzustand
Solid
Farbe
Off-White
InChI
InChI=1S/C21H21N3O3/c1-11-8-13(9-23-20(11)22-3)15-6-7-16-18(12(15)2)24(14-4-5-14)10-17(19(16)25)21(26)27/h6-10,14H,4-5H2,1-3H3,(H,22,23)(H,26,27)

Sicherheit und Regulatorisches

Sicherheitsangaben dienen nur zur Orientierung und ersetzen weder das Sicherheitsdatenblatt (SDB) des Lieferanten noch geltende Vorschriften oder eine fachliche Bewertung.

Toxikologische Informationen

Effects During Pregnancy and Lactation◉ Summary of Use during Lactation

Sicherheitsdaten

wgk
WGK 3
Speicherklasse
11 - Combustible Solids

Chemie und Industrie

Pharmakologische Informationen

ATC Code · 2 Einträge

D - Dermatologicals

QD - Dermatologicals

Protein BindingThe plasma protein binding of [14 C]-ozenoxacin is moderate at ~80-85% and does not appear to be dependent on concentration.
Pharmacodynamics · 1 Eintrag

Although the exposure response relationship for ozenoxacin after it has been applied topically has not yet been studied, a formal relationship is unlikely because systemic exposure of ozenoxacin following its topical application has been measured to be negligible.

Mechanism of Action · 1 Eintrag

Ozenoxacin is a quinolone antibiotic drug. And, like most quinolones, ozenoxacin predominately executes its mechanism of action by entering into bacterial cells and acting to inhibit the bacterial DNA replication enzymes DNA gyrase A and topoisomerase IV. As DNA gyrase A and topoisomerase IV are essential to bacterial DNA replication activities including supercoiling, supercoil relaxation, chromosomal condensation, chromosomal decatenation and more, their inhibition is the principal action of ozenoxacin's mechanism and it has been demonstrated to be bactericidal against *S. aureus* and *S. pyogenes* organisms.

Metabolism/MetabolitesStudies have demonstrated that ozenoxacin is not metabolized in the presence of fresh human skin discs and is minimally metabolized in human hepatocytes.
FDA Pharmacological Classification · 5 Einträge

V0LH498RFO

OZENOXACIN

Established Pharmacologic Class [EPC] - Quinolone Antimicrobial

Chemical Structure [CS] - Quinolones

Ozenoxacin is a Quinolone Antimicrobial.

MeSH Pharmacological Classification · 2 Einträge

Substances that inhibit the growth or reproduction of BACTERIA.

Compounds that inhibit the activity of DNA TOPOISOMERASES.

Anbieter

Wird geladen…

Öffentliche Anfragen

Wird geladen…

Zugehörige Reaktionen

0
Reaktionsaufzeichnung erstellen

Keine Reaktionsaufzeichnungen unter den aktuellen Filterkriterien.

Notizen zur Verbindung

Wird geladen…

Auf dieser SeiteGrundinformationenÜberblickNamen und BezeichnerEigenschaftenSicherheit und RegulatorischesChemie und IndustrieZugehörige ReaktionenNotizen zur Verbindung
245765-41-7
PubChem CID
9863827
DTXSID
DTXSID00947446
ChEMBL
CHEMBL3990047
ChEBI
CHEBI:136050
UNII
V0LH498RFO
Nikkaji
J1.697.283E
InChIKey
XPIJWUTXQAGSLK-UHFFFAOYSA-N
SMILES
N1(C2CC2)C2=C(C=CC(C3=CC(C)=C(NC)N=C3)=C2C)C(=O)C(C(O)=O)=C1
Absorption, Distribution and Excretion · 4 Einträge

Four studies were performed in which varying strengths of ozenoxacin cream, up to 2% (twice the concentration of the marketed formulation), were administered to 110 patients. Three of the studies examined systemic absorption in healthy subjects and in subjects having impetigo. The studies were performed with either single or repeated application of up to 1 g ozenoxacin cream to intact or abraded skin (up to 200 cm squared surface area). No systemic absorption was seen in 84 of 86 subjects, and negligible systemic absorption was seen at the level of detection (0.489 ng/mL) in 2 subjects.

Studies regarding elimination and excretion have not yet been investigated in humans due to the negligible systemic absorption observed in clinical studies.

Ozenoxacin undergoes negligible systemic absorption after its topical administration. Subsequently, since negligible systemic absorption of ozenoxacin was observed in clinical studies, tissue distribution has not been investigated in humans either.

Ozenoxacin undergoes negligible systemic absorption after its topical administration.

Anwendungen · 2 Einträge

BeschreibungOzenoxacin is a novel, nonfluorinated quinolone antibiotic discovered by Toyama Chemical Co. Ltd. and developed by Maruho Co. Ltd. Ozenoxacin was approved by the PMDA of Japan in September 2015 for the treatment of acne and skin infections. Ozenoxacin shows potent antibacterial activity against anaerobic and aerobic, gram-positive and -negative bacteria, especially those implicated in superficial skin infections such as S. aureus, Staphylococcus epidermidis, and Propionibacterium acnes. The mechanism of action of ozenoxacin involves the drug’s affinity for DNA gyrase and DNA topoisomerase IV and upon binding triggers bacterial apoptosis.

VerwendenOzenoxacin is a non-fluorinated topical quinolone. It exhibits antimicrobial activity againstpropionibacteria and staphylococci. Ozenoxacin can be used to treat acne and superficial skin infections.